10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

VHL Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a partial recombinant VHL.
Catalog # AT4511a

Product Information

Application	WB, IF, E
Primary Accession	P40337
Other Accession	NM_000551
Reactivity	Human
Host	mouse
Clonality	monoclonal
Isotype	IgG2b Kappa
Clone Names	1G12
Calculated MW	24153

Additional Information

Gene ID	7428
Other Names	Von Hippel-Lindau disease tumor suppressor, Protein G7, pVHL, VHL
Target/Specificity	VHL (NP_000542, 1 a.a. ~ 110 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Dilution	WB~~1:500~1000 IF~~1:50~200 E~~N/A
Format	Clear, colorless solution in phosphate buffered saline, pH 7.2 .
Storage	Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Precautions	VHL Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.


Background

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.


References

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Pe?a C, et al. Clin Cancer Res, 2010 Sep 14. PMID 20651059.Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.A Large-scale genetic association study of esophageal adenocarcinoma risk. Liu CY, et al. Carcinogenesis, 2010 Jul. PMID 20453000.Clinical and molecular features of familial and sporadic cases of von Hippel-Lindau disease from Mexico. Chacon-Camacho OF, et al. Clin Experiment Ophthalmol, 2010 Apr. PMID 20447124.VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Montani M, et al. Am J Surg Pathol, 2010 Jun. PMID 20431476.

Images




Antibody Reactive Against Recombinant Protein.Western Blot detection against Immunogen (38.21 KDa) .




Western Blot analysis of VHL expression in transfected 293T cell line by VHL monoclonal antibody (M01), clone 1G12.

Lane 1: VHL transfected lysate(19.7 KDa).
Lane 2: Non-transfected lysate.



Immunofluorescence of monoclonal antibody to VHL on HeLa cell . [antibody concentration 10 ug/ml]

Detection limit for recombinant GST tagged VHL is approximately 0.1ng/ml as a capture antibody.



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.